30 October 2017
Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers
ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its...